Cargando…

Joint association of patients’ sex and PD‐L1 expression with overall survival benefits and tumor‐immune microenvironment in immune checkpoint inhibitors for cancers

Detalles Bibliográficos
Autores principales:	Li, Anlin, Chen, Yongjian, Zhang, Wenda, Zhong, Haitao, Ou, Qiyun, Gu, Yang, Xia, Junqing, Lin, Dagui, Fu, Tuping, Liu, Ruixin, Hu, Hai, Yu, Yunfang, Yao, Herui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403698/ https://www.ncbi.nlm.nih.gov/pubmed/32508054 http://dx.doi.org/10.1002/ctm2.92

Ejemplares similares

Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants
por: Yu, Yunfang, et al.
Publicado: (2020)

Association of immune checkpoint inhibitor with survival in patients with cancers with protein tyrosine phosphatase receptor T mutation
por: He, Zifan, et al.
Publicado: (2020)

Novel blood‐based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non‐small‐cell lung cancer: Results from two multicenter, randomized clinical trials
por: Yu, Yunfang, et al.
Publicado: (2020)

Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer
por: Yu, Yunfang, et al.
Publicado: (2020)

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer: A Meta-analysis and Individual Patient–Level Analysis
por: Yu, Yunfang, et al.
Publicado: (2019)

Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy
por: Lin, Lili, et al.
Publicado: (2023)

Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma
por: Ou, Qiyun, et al.
Publicado: (2020)

Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-Analysis of Randomized Clinical Trials and Propensity Score Matching of Multicenter Cohort Study
por: Ren, Wei, et al.
Publicado: (2022)

A Comprehensive Analysis of Programmed Cell Death-Associated Genes for Tumor Microenvironment Evaluation Promotes Precise Immunotherapy in Patients with Lung Adenocarcinoma
por: Huang, Yunxi, et al.
Publicado: (2023)

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition
por: Newton, Jared M., et al.
Publicado: (2019)

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment
por: Yi, Ruibin, et al.
Publicado: (2020)

Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study
por: Yu, Yunfang, et al.
Publicado: (2021)

Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
por: Jia, Yunlong, et al.
Publicado: (2020)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
por: Krueger, Janna, et al.
Publicado: (2021)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018)

Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
por: Zemek, Rachael M., et al.
Publicado: (2020)

The regulation of immune checkpoints by the hypoxic tumor microenvironment
por: Hu, Min, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
por: Ghouzlani, Amina, et al.
Publicado: (2021)

A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma
por: Ouyang, Wenhao, et al.
Publicado: (2022)

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment
por: Kim, Young-Dae, et al.
Publicado: (2020)

A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
por: Ohta, Akio
Publicado: (2016)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
por: Xu, Yaolin, et al.
Publicado: (2021)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
por: Lin, Xinqing, et al.
Publicado: (2022)

Identification of a tumor immune-inflammation signature predicting prognosis and immune status in breast cancer
por: Liu, Yajing, et al.
Publicado: (2023)

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
por: Baba, Yoshifumi, et al.
Publicado: (2020)

The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis
por: Ma, Jiajia, et al.
Publicado: (2022)

Prediction of overall survival and response to immune checkpoint inhibitors: An immune-related signature for gastric cancer
por: Wang, Zheng, et al.
Publicado: (2021)

Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival
por: Weingarden, Alexa R, et al.
Publicado: (2022)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era
por: Lamba, Nayan, et al.
Publicado: (2022)

Commentary: A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
por: Vaupel, Peter, et al.
Publicado: (2016)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
por: Li, Zihui, et al.
Publicado: (2020)

Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment
por: Talaat, Iman M., et al.
Publicado: (2022)

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
por: Tang, Tianyu, et al.
Publicado: (2021)

LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors
por: He, Ziyi, et al.
Publicado: (2023)

PD-1 and its ligands are important immune checkpoints in cancer
por: Dong, Yinan, et al.
Publicado: (2016)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2019)

Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition
por: Zboralski, Dirk, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_808uhv8nq5rh85ip9qui40mkum